Plain-English translation of NCT05897320 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help prevent episodic migraines in children and teenagers. is given as a single infusion through an IV (a small tube in your arm), and researchers want to see if it reduces the number of migraine days children experience. The medication works differently than pain relievers — it's designed to help prevent migraines from happening in the first place.
Many children and teenagers suffer from frequent migraines that can interfere with school, activities, and quality of life. While some migraine treatments exist, doctors are looking for new options that may work better and more safely for young people.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll first go through a 4-week screening period where you track your headaches daily using an app or online diary. Then you'll receive a single intravenous infusion — either the new medication, a lower dose of the medication, or a placebo (a non-active treatment) — and researchers will follow up with you over several weeks to see how many migraine days you experience. The study uses a 'double-blind' design, meaning neither you nor the researchers will know which treatment you received, to keep the results fair and unbiased.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States